rnai-based therapeutics for the treatment of cmv

Cytomegalovirus (cmv) is an opportunistic herpesvirus that can cause a chronic infection in its host and live there permanently. hiv patients and recipients of organ transplants are among the groups of people with immune system defects who are afflicted by this virus. because of the unique life cycle, latency, and mutations of this virus, cmv infection continues to be a major global health concern. cmv has been treated with antiviral medications such as cidofovir, foscarnet, ganciclovir, and valganciclovir. more recent medications, like letermovir and maribavir, have also shown promise in the treatment of cmv. nevertheless, among the issues with these treatments are their toxicity, dosage restrictions, and adverse effects like kidney failure and bone marrow suppression. however, medication resistance in ill patients has prompted researchers to look for ways to make these medications better as well as develop novel therapeutic approaches. rnai-based therapeutics presents a potential treatment option for cmv infection that is less toxic than conventional medications. pharmaceutical advancements have made it possible for rnai-based medications to enter the clinical phase, making this strategy a reliable and effective therapeutic approach. through the targeted expression of key cmv virus proteins, this technique can specifically stop the virus from spreading. in treating cmv with rnai-based therapeutics, the most significant developments and difficulties are discussed in this article.